NEW YORK, May 25, 2016 /PRNewswire/ --
The Biotech arena may not be in its best shape right now, but
this does not mean investors are sidelining stocks in this space.
Here are today's ActiveWallSt.com highlights: Juno Therapeutics
Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx
Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals
Inc. (NASDAQ: ICPT). Get the free access these stocks' technical
alerts by clicking below:
http://www.activewallst.com/
At the close on Tuesday, shares in Juno Therapeutics Inc., a
biopharma Company, which engages in developing cell-based cancer
immunotherapies, gained 0.47%, ending the day at $40.38. The stock recorded a trading volume of
762,812 shares. The Company's shares have advanced 18.80% in the
previous three months. The stock is trading above its 50-day moving
average by 0.97%. Moreover, shares of Juno Therapeutics have a
Relative Strength Index (RSI) of 55.42. Register now and access
free trade alerts on JUNO at:
http://www.activewallst.com/
Shares in Immunomedics Inc., the New
Jersey headquartered clinical-stage biopharma Company, ended
the day 1.90% higher at $4.29. A
total volume of 2.34 million shares was traded, which was above
their three months average volume of 1.03 million shares. In the
last month and the previous three months, the stock has surged
30.79% and 103.32%, respectively. Additionally, the Company's
shares have advanced 39.74% since the start of this year. The stock
is trading above its 50-day and 200-day moving averages by 36.67%
and 66.84%, respectively. Furthermore, shares of Immunomedics have
an RSI of 72.79. Visit us today and activate your complimentary
trade alerts on IMMU at:
http://www.activewallst.com/
On Tuesday, shares in Ultragenyx Pharmaceutical Inc. finished
4.74% higher at $68.28. A total
volume of 696,474 shares was traded, which was above their three
months average volume of 598,150 shares. The Company focuses on the
identification, acquisition, development, and commercialization of
various products for the treatment of rare and ultra-rare genetic
diseases in the U.S. The stock has advanced 8.83% in the previous
three months. The Company's shares are trading above their 50-day
moving average by 5.59%. Additionally, Ultragenyx Pharmaceutical's
stock has an RSI of 59.57. Trade alert on RARE is available for
free at:
http://www.activewallst.com/
New York-based biopharma
Company, Intercept Pharmaceuticals Inc.'s stock recorded a trading
volume of 298,822 shares at the end of yesterday's session and
closed the day at $139.80, gaining
0.87%. The stock has advanced 24.32% in the previous three months.
The Company's shares are trading above their 50-day moving average
by 0.83%. Additionally, shares of Intercept Pharmaceuticals have an
RSI at 53.15. Complimentary alert on ICPT is accessible at:
http://www.activewallst.com/
--
Active Wall Street:
Active Wall Street (AWS) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. AWS has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
AWS has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by AWS. AWS is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
AWS, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. AWS, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, AWS, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither AWS nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.activewallst.com
CONTACT
For any questions, inquiries, or comments reach out to us directly
at:
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
Email: info@activewallst.com
Phone number: 1-858-257-3144
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA